Image
Evidence Based Best Practiceâ„¢

Evolving Management Strategies for Moderate-To-Severe Atopic Dermatitis

Looking Beyond Barriers to Optimize Therapy

Meeting Slides

eBook Reader

  Apple iBooks Google Play  

 

Guidelines

Guidelines of care for the management of atopic dermatitis: part 1. Diagnosis and assessment of atopic dermatitis.

Eichenfield LF, et al. J Am Acad Dermatol. 2014;70(2):338-351.

Guidelines of care for the management of atopic dermatitis: part 2. Management and treatment of atopic dermatitis with topical therapies.

Eichenfield LF, et al. J Am Acad Dermatol. 2014;71(1):116-132.

Guidelines of care for the management of atopic dermatitis: part 3. Management and treatment with phototherapy and systemic agents.

Sidbury R, et al. J Am Acad Dermatol. 2014;71(2):327-349

Guidelines of care for the management of atopic dermatitis: part 4. Prevention of disease flares and use of adjunctive therapies and approaches.

Sidbury R, et al. J Am Acad Dermatol. 2014;71(6):1218-1233

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I.

Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2018;32(5):657-682.

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II.

Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2018;32(6):850-878.

Patient Resources

International Eczema Council

Founded in late 2014, the International Eczema Council (IEC) is a global nonprofit organization led by dermatology experts on atopic dermatitis. The IEC is dedicated to increasing the understanding of atopic dermatitis and promoting its optimal management through research, education, and patient/family care.

National Eczema Association

The National Eczema Association is a nonprofit organization founded in 1988 to improve the health and quality of life for individuals with eczema through research, support, and education.

Clinical Assessment Tools

Eczema Area and Severity Index (EASI)

EASI is a clinician assessment tool designed to measure clinical severity of atopic dermatitis. Severity scores can range from 0 (clear) to 72 (very severe). (Hanifin JM, et al. Exp Dermatol. 2001;10(1):11-18).

Investigator Global Assessment (IGA)

The IGA is a clinician assessment strategy designed to provide a snapshot of overall disease severity in dermatologic clinical trials. (Futamura M, et al. J Am Acad Dermatol. 2016;74(2):288-294).

Scoring Atopic Dermatitis (SCORAD)

SCORAD is a clinical tool used to assess the extent and severity of eczema. (Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186(1):23-31.)

Suggested Readings

 

Atopic Dermatitis Overview and Pathogenesis

 

Epidemiology of atopic dermatitis in adults: results from an international study.

Barbarot S, et al. Allergy. 2018;73(6):1284-1293.

Association between atopic dermatitis and serious cutaneous, multiorgan and systemic infections in US adults.

Narla S, Silverberg JI. Ann Allergy Asthma Immunol. 2018;120(1):66-72.

Eczema and cardiovascular risk factors in 2 US adult population studies.

Silverberg JI, Greenland P. J Allergy Clin Immunol. 2015;135(3):721-728.

Staphylococcus aureus density on lesional and nonlesional skin is strongly associated with disease severity in atopic dermatitis.

Tauber M, et al. J Allergy Clin Immunol. 2016;137(4):1272-1274.

Moving toward endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker analysis.

Thijs JL, et al. J Allergy Clin Immunol. 2017;140(3):730-737.

 

Patient Burden and Comorbidities

 

The self-assessed psychological comorbidities of prurigo in European patients: a multicentre study in 13 countries.

Brenaut E et al. J Eur Acad Dermatol Venereol. 2018 Jun 19. doi: 10.1111/jdv.15145. [Epub ahead of print].

Patient burden is associated with alterations in quality of life in adult patients with atopic dermatitis: results from the ECLA study.

Misery L, et al. Acta Derm Venereol. 2018;98:713-714.

Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis.

Simpson EL, et al. JAMA Dermatol. 2018;154(8):903-912.

Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab—clinical characteristics and treatment.

Wollenberg A, et al. J Allergy Clin Immunol Pract. 2018 Feb 9. doi: 10.1016/j.jaip.2018.01.034. [Epub ahead of print].

 

Management of Atopic Dermatitis

 

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

Blauvelt A, et al. Lancet. 2017;389(10086):2287-2303.

Dupilumab with concomitant topical corticosteroids in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A, or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).

de Bruin-Weller M, et al. Br J Dermatol. 2018;178(5):1083-1101.

Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement.

Drucker AM, et al. Br J Dermatol. 2018;178(3):768-775.

Translating atopic dermatitis management guidelines into practice for primary care providers.

Eichenfield LF, et al. Pediatrics. 2015;136(3):554-565.

Anti-interleukin-31 receptor A antibody for atopic dermatitis.

Ruzicka T, et al. N Engl J Med. 2017;376(9):826-835.

Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.

Simpson EL, et al. N Engl J Med. 2016;375(24):2335-2348.

Interactive Presentation

Clinical Insights Into Atopic Dermatitis Pathogenesis

Narrated by Jeffrey M.Weinberg, MD


Patient Interview

With Amanda


Patient Interview

With Sanjeev


Activity
Clinical Issues in Atopic Dermatitis

Discussions and Debates About Managing Moderate-to-Severe Disease

Activity
Clinical Issues in Atopic Dermatitis

Debates and Discussions About Managing Moderate-to-Severe Disease

Relevant Resources

Clinical Updates in Systemic Lupus Erythematosus

Improved Diagnostic and Management Strategies

Advances in Immunosupressive Therapy for Solid Organ Transplantation

Long-Term Management Strategies to Improve Patient Outcomes

Clinical Updates on the Management of Gout

Evidence-Based Strategies for Improved Patient Outcomes

Managing Gout in Primary Care

Evolving Strategies for Diagnosis and Long-Term Management

Improving Outcomes in Rheumatoid Arthritis

Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms

Clinical Updates in Rheumatoid Arthritis

Evolving Treatment Algorithms and Expert Perspectives on Biosimilars

Going Deeper on Atopic Dermatitis

Pathophysiology to the Management of Moderate-to-Severe Disease

Clinical Updates in Rheumatoid Arthritis

New Strategies to Target Remission and Individualize Comprehensive Care

Looking Beneath The Surface In Atopic Dermatitis

Targeting Immune Dysregulation and Delivering Comprehensive Care

Evolving Treatment Paradigms For Rheumatoid Arthritis

Translating Comprehensive Patient Evaluations Into Personalized Therapy

Clinical Updates in Rheumatoid Arthritis

New Perspectives on Targeting Remission and Individualizing Therapy

A Better Look at Rheumatoid Arthritis

Using Imaging to Improve Patient Outcomes

Clinical Issues in Rheumatoid Arthritis

Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs

Pathways to Better Outcomes in Systemic Lupus Erythematosus

Translating Pathophysiology into Targeted Treatments